MX2017006516A - Tratamiento de la atrofia de piel con una combinacion de acido triyodotiroacetico (triac) y dehidroepiandrosterona (dhea). - Google Patents

Tratamiento de la atrofia de piel con una combinacion de acido triyodotiroacetico (triac) y dehidroepiandrosterona (dhea).

Info

Publication number
MX2017006516A
MX2017006516A MX2017006516A MX2017006516A MX2017006516A MX 2017006516 A MX2017006516 A MX 2017006516A MX 2017006516 A MX2017006516 A MX 2017006516A MX 2017006516 A MX2017006516 A MX 2017006516A MX 2017006516 A MX2017006516 A MX 2017006516A
Authority
MX
Mexico
Prior art keywords
triac
dhea
combination
skin atrophy
skin
Prior art date
Application number
MX2017006516A
Other languages
English (en)
Other versions
MX363010B (es
Inventor
Gregory Batcheller Derek
Johannsson Gudmundur
Faergemann Jan
Ohlsson Claes
Johnsson Jörgen
Törnell Jan
Original Assignee
Trophea Dev Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trophea Dev Ab filed Critical Trophea Dev Ab
Publication of MX2017006516A publication Critical patent/MX2017006516A/es
Publication of MX363010B publication Critical patent/MX363010B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El objetivo del presente estudio es investigar el efecto de una combinación del ácido triyodotiroacético (TRIAC) y dehidroepiandrosterona (DHEA) en comparación con el TRIAC, DHEA o un placebo solo sobre el efecto inducido por corticosteroides en la síntesis de colágeno en humanos. Participaron seis voluntarios varones humanos sanos con edades de 40-65 años. Cuatro zonas de la piel abdominal se pre-trataron durante 3 semanas con crema de valerato de betametasona. Las mismas áreas después se trataron con una de las siguientes alternativas en el mismo vehículo de crema: TRIAC, DHEA, TRIAC+DHEA y placebo durante 2 semanas. Después se suscitaron ampollas de succión en cada una de estas áreas con una bomba de vacío. El fluido de ampolla de cada área se recolectó y se congeló hasta su análisis. El análisis del propéptido amino terminal del procolágeno tipo I humano (PINP) en el fluido de ampolla de succión se realizó con el uso de un kit de inmunoensayo disponible comercialmente (Orion Diagnostics). Este estudio por primera vez ha mostrado que una combinación de TRIAC y DHEA podría estimular eficazmente la síntesis de colágeno en la piel pretratada con valerato de betametasona, mostrado por un incremento en PINP, y que la combinación fue más eficaz que el TRIAC o la DHEA solos. Esta combinación podría ser utilizada para tratar con eficacia la atrofia de piel inducida por corticosteroides en atrofia de piel. También se podría utilizar para tratar la atrofia de piel debida a otras circunstancias, tales como la piel dañada por ejemplo por el sol y atrofiaa de piel debida a una alta edad. Otra aplicación interesante sería combinar el TRIAC y DHEA con un potente corticosteroide con el fin de evitar la atrofia de piel inducida por corticosteroides. Si esta combinación todavía es eficaz en el tratamiento de eczema y psoriasis y sin el riesgo de atrofia de piel, esta combinación será un gran avance para el uso de corticosteroides tópicos potentes.
MX2017006516A 2014-11-25 2015-11-24 Tratamiento de la atrofia de piel con una combinacion de acido triyodotiroacetico (triac) y dehidroepiandrosterona (dhea). MX363010B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201470737 2014-11-25
PCT/EP2015/077401 WO2016083325A1 (en) 2014-11-25 2015-11-24 Treatment of skin atrophy with a combination of triiodothyroacetic acid (triac) and dehydroepiandrosterone (dhea)

Publications (2)

Publication Number Publication Date
MX2017006516A true MX2017006516A (es) 2018-01-25
MX363010B MX363010B (es) 2019-03-04

Family

ID=52133757

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006516A MX363010B (es) 2014-11-25 2015-11-24 Tratamiento de la atrofia de piel con una combinacion de acido triyodotiroacetico (triac) y dehidroepiandrosterona (dhea).

Country Status (18)

Country Link
US (2) US10413555B2 (es)
EP (1) EP3223808B1 (es)
JP (1) JP6666911B2 (es)
KR (1) KR20170086597A (es)
CN (1) CN106999457B (es)
AU (1) AU2015352677B2 (es)
BR (1) BR112017010778A2 (es)
CA (1) CA2968611A1 (es)
DK (1) DK3223808T3 (es)
ES (1) ES2714078T3 (es)
HU (1) HUE042970T2 (es)
IL (1) IL252203A0 (es)
MX (1) MX363010B (es)
PL (1) PL3223808T3 (es)
PT (1) PT3223808T (es)
RU (1) RU2017121884A (es)
WO (1) WO2016083325A1 (es)
ZA (1) ZA201702989B (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH642851A5 (en) 1980-02-13 1984-05-15 Berema Sa Medicinal compositions for the treatment of cellulite
GB9214202D0 (en) 1992-07-03 1992-08-12 Leo Pharm Prod Ltd Chemical compounds
PT831769E (pt) 1995-06-07 2004-02-27 Karobio Ab Novas utilizacoes para as hormonas da tiroide ou compostos semelhantes as hormonas da tiroide
DK1021204T3 (da) * 1997-09-26 2006-05-08 Noven Pharma Bioadhæsive præparater og fremgangsmåder til topisk administration af aktive midler
FR2808683B1 (fr) 2000-05-15 2003-05-23 Oreal Utilisation de la dhea et/ou ses precurseurs et derives chimiques et/ou biologiques, dans une composition notamment cosmetique, pour prevenir ou traiter l'atrophie de l'epiderme
US20050271739A1 (en) 2004-06-08 2005-12-08 Wang Xiang H Methods and compositions for accelerating alcohol metabolism
US20080305096A1 (en) * 2007-06-07 2008-12-11 Unicity International, Inc. Method and composition for providing controlled delivery of biologically active substances
US20100009970A1 (en) 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases

Also Published As

Publication number Publication date
AU2015352677B2 (en) 2019-10-24
US20170319598A1 (en) 2017-11-09
HUE042970T2 (hu) 2019-07-29
RU2017121884A (ru) 2018-12-26
EP3223808B1 (en) 2019-01-09
BR112017010778A2 (pt) 2018-01-09
RU2017121884A3 (es) 2019-04-05
US20190216822A1 (en) 2019-07-18
MX363010B (es) 2019-03-04
EP3223808A1 (en) 2017-10-04
US10413555B2 (en) 2019-09-17
KR20170086597A (ko) 2017-07-26
PT3223808T (pt) 2019-02-04
CA2968611A1 (en) 2016-06-02
PL3223808T3 (pl) 2019-07-31
JP6666911B2 (ja) 2020-03-18
ZA201702989B (en) 2019-10-30
ES2714078T3 (es) 2019-05-27
WO2016083325A1 (en) 2016-06-02
CN106999457A (zh) 2017-08-01
DK3223808T3 (en) 2019-03-25
IL252203A0 (en) 2017-07-31
CN106999457B (zh) 2020-02-11
JP2017535590A (ja) 2017-11-30
AU2015352677A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
PH12016502254A1 (en) Keratin treatment formulations and methods
MX2017013983A (es) Uso de agentes activos durante tratamientos quimicos.
PH12018502634A1 (en) Topical compositions of apremilast
PH12017501487A1 (en) Methods for treating skin
WO2018115097A9 (en) Ophthalmic composition for treatment of dry eye disease
MX2013011835A (es) Composiciones nutricionales que incluyen acidos grasos de cadena ramificada para la curacion de heridas.
MX360469B (es) Composiciones que comprenden mezclas de alcanos semifluorados.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
WO2019067405A3 (en) FORMULATION OF FENFLURAMINE COMPATIBLE WITH A CÉTOGENEOUS REGIMEN
MX2016011841A (es) Composiciones topicas de corticosteroides.
BR112018012022A2 (pt) ?composição, e, método para tratamento ou redução do risco de colestase intra-hepática?
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
NZ741785A (en) 3-cyano-1h-1,2,4-triazol-1-yl compounds and uses thereof for the treatment of hiv
MX2021010989A (es) Formulacion que incluye una combinacion de la hormona beta-endorfina y adrenocorticotropica.
RU2017134440A (ru) Композиции для местного применения, содержащие кортикостероид
WO2013152193A3 (en) Methods of treating proliferative disorders with malate or derivatives thereof
NZ710602A (en) Methods for reducing pyrogenicity in a seaweed extract
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
MX2015017555A (es) Metodos y composiciones para aumentar la movilizacion de las celulas madre.
MX2012013607A (es) Polisacarido de las semillas de tamarindo para usarse en el tatamiento de enfermedades inflamatorias.
WO2014190179A3 (en) Urea silicon gel for scars and hydration treatment and method of using same
MX2016010699A (es) Composiciones y metodos para tratar neutropenia.
WO2015070076A3 (en) Methods and compositions for rejuvenating neuromuscular junctions
MX363010B (es) Tratamiento de la atrofia de piel con una combinacion de acido triyodotiroacetico (triac) y dehidroepiandrosterona (dhea).
BR112018013558A2 (pt) método de tratamento de uma doença hepática em um indivíduo, método de uso de um inibidor de caspase, método para diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação de child-pugh ou seus componentes, composição farmacêutica que compreende um inibidor de caspase, kit, método de tratamento, método de tratamento de cirrose hepática e prevenção de uma classificação meld elevada, método de tratamento de cirrose hepática e prevenção de uma classificação de child-pugh elevada